

## Publications – Ruth Frikke-Schmidt

### CITATION REPORT

H-index Web of Science	Total no. of publications*	Total no. of citations	Total no. of citations without self-citations
44	130	13,009	12,724

\*117 original articles, 5 reviews, 7 letters/commentaries, 1 patent.

### AUTHORSHIP

First*	Second	Sole	Last	Second last	Other co-author
15	25	6	18	7	59

\*One shared first-authorship

### JOURNAL IMPACT FACTOR

Average impact factor*	No. of articles with impact factor above 20*	No. of articles with impact factor between 10 and 20*
14.89	26	15

\*Original articles

### PUBLICATIONS

If more than 20 authors, the first three are listed.

- 1) Agerholm-Larsen B, Tybjærg-Hansen A, **Frikke-Schmidt R**, Grønholdt MLM, Jensen G, Nordestgaard BG. ACE gene polymorphism as a risk factor for ischemic cerebrovascular disease. *Ann Intern Med* 1997;127:346-355.
- 2) **Frikke-Schmidt R**, Arlien-Søborg P, Thorsen S, Jensen HK, Vorstrup S. LDL receptor mutations and apoB mutations are not risk factors for ischemic cerebrovascular disease of the young, but lipids and lipoproteins are. *Eur J Neurol* 1999;6:691-696.
- 3) **Frikke-Schmidt R**, Nordestgaard BG, Agerholm-Larsen B, Schnohr P, Tybjærg-Hansen A. Context dependent and invariant effects of apolipoprotein E genotype on lipids, lipoproteins, and apolipoproteins. A study of 9,060 women and men from the population at large. *J Lipid Res* 2000;41:1812-1822.
- 4) **Frikke-Schmidt R**, Tybjærg-Hansen A, Steffensen R, Jensen G, Nordestgaard BG. Apolipoprotein E genotype: ε32 women are protected while ε43 and ε44 men are susceptible to ischemic heart disease. The Copenhagen City Heart Study. *J Am Coll Cardiol* 2000;35:1192-1197.
- 5) **Frikke-Schmidt R**, Wittrup HH, Tybjærg-Hansen A, Meinertz H, Nordestgaard BG. Apolipoprotein E genotypes predict attendance rates at lipid clinic. *Atherosclerosis* 2000;153:461-468.
- 6) **Frikke-Schmidt R**. Context dependent and invariant associations between APOE genotype and levels of lipoproteins and risk of ischemic heart disease. *Scand J Clin Lab Invest*, 2000;60 Suppl 233:3-26.
- 7) **Frikke-Schmidt R**, Nordestgaard BG, Thudium D, Grønholdt MLM, Tybjærg-Hansen A. APOE genotype predicts AD and other dementia, but not ischemic cerebrovascular disease. *Neurology* 2001;56:194-200.
- 8) **Frikke-Schmidt R**, Nordestgaard BG, Schnohr P, Tybjærg-Hansen A. A common mutation in the low density lipoprotein receptor is associated with a three-fold risk of stroke. The Copenhagen City Heart Study. *Eur Heart J* 2004;25:943-951.
- 9) **Frikke-Schmidt R**, Sing CF, Nordestgaard BG, Tybjærg-Hansen A. Gender and age specific contributions of additional DNA sequence variation in the 5' regulatory region of the APOE gene to prediction of measures of lipid metabolism. *Hum Genet* 2004;115:331-345.
- 10) **Frikke-Schmidt R**, Nordestgaard BG, Jensen G, Tybjærg-Hansen A. Genetic variation in ABC Transporter A1 contributes to HDL cholesterol levels in the general population. *J Clin Invest* 2004;114:1343-1353.

- Editorial by Pajukanta P: Do DNA sequence variants in ABC Transporter A1 contribute to HDL cholesterol in the general population? *J Clin Invest* 2004;114:1244-1247.
- 11) **Frikke-Schmidt R**, Nordestgaard BG, Schnohr P, Steffensen R, Tybjærg-Hansen A. Mutation in ABCA1 predicted risk of ischemic heart disease in the Copenhagen City Heart Study Population. *J Am Coll Cardiol* 2005;46:1516-1520.
  - 12) Stengård JH, Kardina SL, Hamon SC, **Frikke-Schmidt R**, Tybjærg-Hansen A, Salomaa V, Boerwinkle E, Sing CF. Contribution of regulatory and structural variations in APOE to predicting dyslipidemia. *J Lipid Res* 2006;47:318-328.
  - 13) Stene MC, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Zinc finger protein 202, genetic variation, and HDL cholesterol in the general population. *J Lipid Res* 2006;47:944-952.
  - 14) Slatter TL, Williams MJ, **Frikke-Schmidt R**, Tybjærg-Hansen A, Morison IM, McCormick SP. Promoter haplotype of a new ABCA1 mutant influences expression of familial hypoalphalipoproteinemia. *Atherosclerosis* 2006;187:393-400.
  - 15) Stene MC, **Frikke-Schmidt R**, Nordestgaard BG, Steffensen R, Schnohr P, Tybjærg-Hansen A. Zinc Finger Protein 202: A new candidate gene for ischemic heart disease. The Copenhagen City Heart Study. *Atherosclerosis* 2006;188:43-50.
  - 16) **Frikke-Schmidt R**, Sing CF, Nordestgaard BG, Steffensen R, Tybjærg-Hansen A. Subsets of SNPs define rare genotype classes that predict risk of ischemic heart disease. *Hum Genet* 2007;120:865-877.
  - 17) Dyson G, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A, Sing CF. An application of the Patient Rule Induction Method for evaluating the contribution of the apolipoprotein E and lipoprotein lipase genes to predicting ischemic heart disease. *Genet Epidemiol* 2007;31:515-527.
  - 18) Stengard JH, **Frikke-Schmidt R**, Tybjærg-Hansen A, Sing CF. Variation in 5' promoter region of the APOE gene contributes significantly to predicting ischemic heart disease (IHD) in the population at large: the Copenhagen City Heart Study. *Ann Hum Genet* 2007;71:762-771.
  - 19) Danesh J, Erqou S, Walker M et al. Emerging Risk Factors Collaboration: analysis of individual data on lipid and inflammatory markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. *Eur J Epidemiol* 2007;22:839-869.
  - 20) **Frikke-Schmidt R**, Nordestgaard BG, Jensen GB, Steffensen R, Tybjærg-Hansen A. Genetic variation in ABCA1 predicts ischemic heart disease in the general population. *Arterioscler Thromb Vasc Biol* 2008;28:180-186.
  - 21) Ahnström J, Axler O, Jauhiainen M, Salomaa V, Havulinna AS, Ehnholm C, **Frikke-Schmidt R**, Tybjærg-Hansen A, Dahlbäck B. Levels of apolipoprotein M are not associated with the risk of coronary heart disease in two independent case-control studies. *J Lipid Res* 2008 49:1912-1917.
  - 22) **Frikke-Schmidt R**, Nordestgaard BG, Stene MCA, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjærg-Hansen A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. *JAMA* 2008;299:2524-2532.
  - 23) Stene MCA, **Frikke-Schmidt R**, Nordestgaard BG, Grande P, Schnohr P, Tybjærg-Hansen A. Functional promoter variant in zinc finger protein 202 predicts severe atherosclerosis and ischemic heart disease. *J Am Coll Cardiol* 2008;52:369-377.
  - 24) Heid IM, Boes E, Müller M, Kollerits B, Lamina C, Coassin S, Gieger C, Döring A, Klopp N, **Frikke-Schmidt R**, Tybjærg-Hansen A, Brandstätter A, Luchner A, Meitinger T, Wichmann HR, Kronenberg F. A genome-wide association analysis of HDL-cholesterol in the population-based KORA study sheds new light on intergenic regions. *Circ Cardiovasc Genet* 2008;1:10-20.
  - 25) Johansen JS, Bojesen SE, Mylin AK, **Frikke-Schmidt R**, Price PA, Nordestgaard BG. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. *J Clin Oncol* 2008;27:572-578.
  - 26) Nørskov MS, **Frikke-Schmidt R**, Loft S, Tybjærg-Hansen A. High-throughput genotyping of copy number variation in Glutathione S-Transferases M1 and T1 using real-time PCR in 20,687 individuals. *Clin Biochem* 2009;42:201-209.
  - 27) Dyson G, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A, Sing CF. Modifications to the patient rule-induction method that utilize non-additive combinations of genetic and

- environmental effects to define partitions that predict ischemic heart disease. *Genet Epidemiol* 2009;33:317-324.
- 28) Ripa R, Jørgensen E, Baldazzi F, **Frikke-Schmidt R**, Wang Y, Tybjærg-Hansen A, Kastrup J. The influence of genotype on vascular endothelial growth factor and regulation of myocardial collateral blood flow in patients with acute and chronic coronary heart disease. *Scand J Clin Lab Invest* 2009;69:722-728.
- 29) Erqou S, Kaptoge S, Perry PL et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009;302:412-423.
- 30) **Frikke-Schmidt R**. Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. *Atherosclerosis* 2010;208:305-316.
- 31) Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins and risk of vascular disease. *JAMA* 2009;302:1993-2000.
- 32) Kaptoge S, Di Angelantonio E, Lowe G et al. C-reactive protein concentration and the risk of coronary heart disease, stroke and mortality. *Lancet* 2010;375:132-140.
- 33) Stengård JH, Dyson G, **Frikke-Schmidt R**, Tybjærg-Hansen A, Nordestgaard BG, Sing CF. Context dependent association between variation in risk of IHD and variation in the 5' promoter region of the apolipoprotein E gene in Danish females. *Circ Cardiovasc Genet* 2010;3:22-30.
- 34) Sarwar N, Sandhu MS, Ricketts SL et al. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet* 2010;375:1634-1639.
- 35) Thompson S, Kaptoge S, White I et al. Statistical methods for the time-to-event analysis of individual participant data from multiple epidemiological studies. *Int J Epidemiol* 2010;39:1345-1359.
- 36) Nørskov MS, **Frikke-Schmidt R**, Bojesen SE, Nordestgaard BG, Loft S, Tybjærg-Hansen A. Copy number variation in glutathione S-transferase T1 and risk of prostate and corpus uteri cancer in the general population. *Pharmacogenomics J* 2011;11:292-299.
- 37) Sarwar N, Gao P, Kondapally Seshasai SR et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010;375:2215-2222.
- 38) **Frikke-Schmidt R**, Tybjærg-Hansen A, Schnohr P, Jensen G, Nordestgaard BG. Common clinical practice versus new PRIM score in predicting coronary heart disease risk. *Atherosclerosis* 2010;213:532-538.
- 39) Haase CL, Tybjærg-Hansen A, Grande P, **Frikke-Schmidt R**. Genetically elevated apolipoprotein A-I, HDL cholesterol, and risk of ischemic heart disease in the general population. *J Clin Endocrinol Metab* 2010;95:E500-510.
- 40) Karuna R, Holleboom AOG, Motazacker MMM, Kuivenhoven JA, **Frikke-Schmidt R**, Tybjærg-Hansen A, Georgopoulos S, von Eckardstein A, Rentsch KM. Plasma levels of 27-hydroxycholesterol in humans and mice with monogenic disturbances of high density lipoprotein metabolism. *Atherosclerosis* 2011;214:448-455.
- 41) Jon Møller H\*, **Frikke-Schmidt R\***, Nordestgaard BG, Moestrup SM, Tybjærg-Hansen A. Serum soluble CD163 predicts risk of type 2 diabetes in the general population. *Clin Chem* 2011;57:291-297. \*These authors contributed equally to the manuscript.
- 42) Stender S, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Sterol transporter ABCG8 and gallstones in 62,000 individuals from the general population. *Hepatology*, 2011;53:640-648.
- 43) Kondapally Seshasai SR, Kaptoge S, Thompson A et al. Diabetes mellitus, fasting glucose concentration and risk of mortality. *N Engl J Med* 2011;364:829-841.
- 44) Benn M, Tybjærg-Hansen A, Stender S, **Frikke-Schmidt R**, Nordestgaard BG. LDL cholesterol and risk of cancer. Mendelian randomization on 67,000 individuals from the general population. *J Natl Canc Inst* 2011;103:508-519.
- 45) Wormser D, Kaptoge S, Di Angelantonio E et al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. *Lancet* 2011;377:1085-1095.
- 46) Haase CL, **Frikke-Schmidt R**, Nordestgaard BG, Kateifides AK, Kardassis D, Nielsen LB, Johnsen AH, Grande P, Zannis VI, Tybjærg-Hansen A. Mutation in APOAI predicts increased risk of

- ischemic heart disease and total mortality without low HDL cholesterol. *J Intern Med* 2011;270:136-146.
- 47) **Frikke-Schmidt R**. Genetic variation in ABCA1 and risk of cardiovascular disease. *Atherosclerosis*, 2011;218:281-282.
- 48) Nørskov MS, **Frikke-Schmidt R**, Loft S, Nordestgaard BG, Tybjærg-Hansen A. Copy number variation in glutathione S-transferases M1 and T1 and risk of ischemic cardiovascular diseases. Interaction with smoking. *Circ Cardiovasc Genet* 2011;4:418-28.
- 49) Hornstrup LS, Tybjærg-Hansen A, Haase CL, Nordestgaard BG, Grande P, **Frikke-Schmidt R**. Association of the R1141X mutation in ABCC6 and risk of ischemic heart disease, ischemic cerebrovascular disease and death in the general population. *Circ Cardiovasc Genet* 2011;4:534-541.
- 50) Christoffersen M, **Frikke-Schmidt R**, Schnohr P, Jensen G, Appleyard M, Nordestgaard BG, Tybjærg-Hansen A. Xanthlasma palpebrarum predict risk of ischemic heart disease, myocardial infarction, and total death in the general population: a prospective cohort study. *BMJ* 2011;343:d5497.
- 51) Stender S, **Frikke-Schmidt R**, Sethi AA, Nordestgaard BG, Grande P, Tybjærg-Hansen A. Genetic variation in liver X receptor alpha and risk of ischemic vascular disease in the general population. *Arterioscler Thromb Vasc Biol* 2011;31:2990-2996.
- 52) Steiner C, Holleboom AG, Karuna R, Motazacker MM, Kuivenhoven JA, **Frikke-Schmidt R**, Tybjærg-Hansen A, Rohrer L, Rentsch KM, von Eckardstein A. Lipoprotein distribution and serum concentrations of 7alpha hydroxyl-4-cholesten-3-one and bile acids: Effects of monogenic disturbances of high density lipoprotein metabolism. *Clin Science* 2012;122:385-396.
- 53) Bown MJ, Jones GT, Harrison SC et al. Abdominal aortic aneurysm is associated with a variant in the Low-density lipoprotein receptor Related Protein 1 gene, LRP1. *Am J Hum Genet* 2011;89:619-627.
- 54) Rapsomaniki E, White IR, Wood AM et al. A framework for quantifying net benefits of alternative prognostic models. *Stat Med* 2012;31:114-130.
- 55) Haase CL, Tybjærg-Hansen A, Qayyum AA, Schou J, Nordestgaard BG, **Frikke-Schmidt R**. LCAT, HDL cholesterol and ischemic heart disease – a mendelian randomization study of HDL cholesterol in 55,200 individuals. *J Clin Endocrinol Metab* 2012;97:E248-E256.
- 56) Schou J, **Frikke-Schmidt R**, Kardassis D, Thymiakou E, Nordestgaard BG, Jensen G, Grande P, Tybjærg-Hansen A. Functional mutation in ABCG1 predicts ischemic heart disease and myocardial infarction in humans. *Arterioscler Thromb Vasc Biol* 2012;32:506-515.
- 57) Murabito JM, White CC, Kavousi M et al. Association between chromosome 9p21 variants and the ankle-brachial index identified by a meta-analysis of 21 genome-wide association studies. *Circ Cardiovasc Genet* 2012;5:100-112.
- 58) Wassel CL, Lamina C, Nambi et al. Genetic determinants of the ankle-brachial Index: A meta-analysis of a cardiovascular candidate gene 50K SNP panel in the Candidate gene Association Resource (CARE) consortium. *Atherosclerosis* 2012;222:138-147.
- 59) Voight BF, Peloso GM, Orho-Melander M et al. A mendelian randomization study for plasma high-density lipoprotein cholesterol. *Lancet* 2012;380:572-580.
- 60) Di Angelantonio E, Gao P, Pennells L et al. Lipid-related markers and cardiovascular disease prediction. *JAMA* 2012;307:2499-2506.
- 61) Stender S, **Frikke-Schmidt R**, Nordestgaard BG, Grande P, Tybjærg-Hansen A. Genetically elevated bilirubin and risk of ischaemic heart disease: Three mendelian randomization studies and a meta-analysis. *J Intern Med* 2013;273:59-68.
- 62) Schou J, Tybjærg-Hansen A, Møller HJ, Nordestgaard BG, **Frikke-Schmidt R**. ABC transporter genes and risk of type 2 diabetes. *Diabetes Care* 2012;35:2600-2606.
- 63) Christoffersen C, Benn M, Christensen P, Gordts PLSM, **Frikke-Schmidt R**, Tybjærg-Hansen A, Dahlbäck B, Nielsen LB. The plasma concentration of HDL-associated apoM is controlled by the LDL-receptor. *J Lipid Res* 2012;53:2198-2204.
- 64) Johannsen TH, **Frikke-Schmidt R**, Schou J, Nordestgaard BG, Tybjærg-Hansen A. Cholesteryl ester transfer protein and risk of ischemic cardiovascular disease. *J Am Coll Cardiol* 2012;60:2041-2048.

- 65) Stender S, **Frikke-Schmidt R**, Benn M, Nordestgaard BG, Tybjærg-Hansen A. Low density lipoprotein cholesterol and risk of gallstone disease: a mendelian randomization study and meta-analyses. *J Hepatology* 2013;58:126-33.
- 66) Olama AAA, Kote-Jarai Z, Schumacher FR et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. *Hum Mol Genet* 2013;22:408-15.
- 67) Haase CL, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Resequencing of APOA1 in 10,330 individuals from the general population. *PLoS Genetics* 2012;8:e1003063.
- 68) Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, **Frikke-Schmidt R**, Nordestgaard BG. Nonfasting remnant cholesterol as a causal risk factor for ischemic heart disease. *J Am Coll Cardiol* 2013;61:427-36.
- 69) Kaptoge S, Di Angelantonio E, Pennells L et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. *New Engl J Med* 2012;367:1310-20.
- 70) Jørgensen AB, **Frikke-Schmidt R**, West AS, Nordestgaard BG, Grande P, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. *Eur Heart J*. 2013;34:1826-1833.
- 71) Khan YS, Shah T, Prieto D et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke. Systematic review and meta-analysis of 14,015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals. *Int J Epidemiol* 2013;42:475-492.
- 72) Hornstrup LS, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Genetic stabilization of transthyretin, cerebrovascular disease, and life expectancy. *Arterioscler Thromb Vasc Biol* 2013;33:1441-1447.
- 73) Stender S, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Bilirubin as a causal risk factor for gallstone disease: a mendelian randomization study. *JAMA Int Med* 2013;173:1222-1228.
- 74) Singh GM, Danaei G, Farzadfar F et al. The age-specific quantitative effects on metabolic risk factors on cardiovascular diseases and diabetes: a pooled analysis. *PLoS One* 2013;8:e65174.
- 75) Christoffersen M, **Frikke-Schmidt R**, Schnohr P, Jensen GB, Nordestgaard BG, Tybjærg-Hansen A. Visible aging signs and risk of ischemic cardiovascular disease in the general population: a prospective cohort study. *Circulation* 2014;129:990-998.
- 76) Christiansen M, Hedley PL, Theilade J, Stoevring B, Leren TP, Eschen O, Sørensen KM, Tybjærg-Hansen A, Ousager LB, Pedersen LN, **Frikke-Schmidt R**, Aidt FH, Hansen MG, Hansen J, Bloch Thomsen PE, Toft E, Henriksen FL, Bundgaard H, Jensen HK, Kanters JK. Mutations in Danish patients with long QT syndrome and the identification of a large founder family with p.F29L in KCNH2. *BMC Med Genet* 2014 15;31.
- 77) Stender S, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. The ABCG5/G8 cholesterol transporter and myocardial infarction versus gallstone disease. *J Am Coll Cardiol* 2014;63:2121-2128.
- 78) Di Angelantonio E, Gao P, Khan H et al. Glycated haemoglobin measurement and prediction of cardiovascular disease. *JAMA* 2014;311:1225-1233.
- 79) Lusk C, Dyson G, Clark A, Ballantyne C, **Frikke-Schmidt R**, Tybjærg-Hansen A, Boerwinkle E, Sing CF. Validated context dependent associations of coronary heart disease risk with genotype variation in the chromosome 9p21 region: the ARIC study. *Hum Genet* 2014;133:1105-1116.
- 80) Jørgensen AB, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Loss-of-function mutations in *APOC3* and reduced risk of ischemic vascular disease. *N Engl J Med* 2014;371:32-41.
- 81) Holmes MV, **Frikke-Schmidt R**, Melis D et al. A systematic review and meta-analysis of 130,000 individuals shows smoking does not modify the association of APOE genotype on risk of coronary heart disease. *Atherosclerosis* 2014;237:5-12.
- 82) **Frikke-Schmidt R**, Tybjærg-Hansen A, Dyson G, Haase CL, Benn M, Nordestgaard BG, Sing A. Subgroups at high risk for ischemic heart disease: identification and validation in 67,000 individuals from the general population. *Int J Epidemiol* 2015;44:117-128.
- 83) Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. Plasma levels of apolipoprotein E and risk of dementia in the general population. *Ann Neurol* 2015;77:301-311.

- 84) White IR, Rapsomaniki I, Tipping RW et al. Covariate adjusted measures of discrimination for survival data. *Biom J*. 2015;57:592-613.
- 85) Lauersen JH, Søndergaard HB, Albrechtsen A, **Frikke-Schmidt R**, Koch-Henriksen N, Soelberg Sørensen P, Sellebjerg F, Oturai A. genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. *Mult Scler J* 2015;21:1414-1422.
- 86) Lauridsen BK, Stender S, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Genetic variation mimicking the effect of ezetimibe associates with increased risk of symptomatic gallstone disease. *Eur Heart J* 2015;36:1601-1608.
- 87) Nordestgaard LT, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. A loss-of-function mutation in ABCA1 and risk of Alzheimer disease and cerebrovascular disease. *Alzheimers Dement* 2015;11:1430-1438.
- 88) Haase CL, Tybjærg-Hansen, Nordestgaard BG, **Frikke-Schmidt R**. Genetically reduced high-density lipoprotein cholesterol and risk of type 2 diabetes: a mendelian randomization study. *Diabetes* 2015;64:3328-3333.
- 89) Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. Plasma levels of apolipoprotein E, associations with lipids, lipoproteins, and apolipoproteins, and with risk of ischemic heart disease in the general population. *Atherosclerosis* 2016;246:63-70.
- 90) Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. Correlations between plasma levels of apolipoprotein E, associations with lipids, lipoproteins, and apolipoproteins, and with risk of ischemic heart disease in the general population. *Data Brief* 2016;6:923-932.
- 91) Zanon P, Khetarpal SA, Larach DB et al. A rare loss-of-function variant in scavenger receptor class B type I (SCARB1) raises HDL cholesterol and increases risk of coronary disease. *Science* 2016;352:1166-1171.
- 92) Wellington CL, **Frikke-Schmidt R**. Relation between plasma and brain lipids. *Curr Opin Lipidol* 2016;2:225-232.
- 93) Christoffersen M, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Genetic variation in WRN and ischemic stroke: General population studies and meta-analyses. *Exp Gerontol* 2017;89:69-77.
- 94) Marouli E, Graff M, Medina-Gomez C et al. Rare and low-frequency coding variants alter human adult height. *Nature* 2017;542:186-190.
- 95) Nyberg M, Egelund J, Mandrup CM, Andersen CB, Hansen KMBE, Hergel IMF, Valbak-Andersen N, **Frikke-Schmidt R**, Stallknecht B, Bangsbo J, Hellsten Y. Leg vascular and skeletal muscle mitochondrial adaptations to aerobic high-intensity exercise training are enhanced in the early postmenopausal phase. *J Physiol* 2017;595:2969-2983.
- 96) Nordestgaard LT, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. Body mass index and risk of Alzheimer disease: A mendelian randomization study of 399,536 individuals. *JCEM* 2017;102:2310-2320.
- 97) Benn M, Nordestgaard BG, **Frikke-Schmidt R**, Tybjærg-Hansen A. Low LDL-cholesterol, PCSK9 and HMGCR genetic variation, and risk of neurodegenerative disease: a mendelian randomization study. *BMJ* 2017;357:j1648.
- 98) Kessing LV, Munkholm K, Faurholt-Jepsen M, Miskowiak K, Nielsen LB, **Frikke-Schmidt R**, Ekstrøm C, Winther O, Pedersen BK, Poulsen HE, McIntyre RS, Kapczynski F, Gattaz WF, Bardram J, Frost M, Mayora O, Knudsen GM, Phillips M, Vinberg M. The Bipolar Illness Onset study – research protocol for the BIO cohort study. *BMJ Open* 2017;7:e015462.
- 99) Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. Plasma apolipoprotein E levels and risk of dementia – a mendelian randomization study of 106,562 individuals. *Alzheimers Dement* 2018;14:71-80.
- 100) Shepherd L, Borges AH, Harvey R et al. The extent of B-cell activation and dysfunction preceding lymphoma development in HIV positive people. *HIV Med* 2018;19:90-101.
- 101) Mandrup C, Egelund J, Nyberg M, Enevoldsen LH, Kjær A, Clemmensen A, Christen AN, Suetta C, **Frikke-Schmidt R**, Steenberg DE, Wojtaszewski JFP, Hellsten Y, Stallknecht BM. Effects of menopause and high-intensity training on insulin sensitivity and muscle metabolism. *Menopause* 2018; 25:165-175.

- 102) Lundberg Slingsby MH, Nyberg M, Egelund J, Mandrup CJ, **Frikke-Schmidt R**, Kirkby NS, Hellsten Y. Aerobic exercise training lowers platelet reactivity and improves platelet sensitivity to prostacyclin in pre- and postmenopausal women. *J Thromb Haemost* 2017;15:2419-2431.
- 103) Zhao W, Rasheed A, Tikkanen E et al. Identification of new susceptibility loci for type 2 diabetes and shared etiological pathways with coronary heart disease. *Nat Genet* 2017;49:1450-1457.
- 104) Liu DJ, Peloso FM, Yu H et al. Exome-wide association study of plasma lipids in >300,000 individuals. *Nat Genet* 2017;49:1758-1766.
- 105) Lauridsen BK, Stender S, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Using genetics to explore whether the cholesterol-lowering drug ezetimibe may cause an increased risk of cancer. *Int J Epidemiol* 2017;46:1777-1785.
- 106) Grunnet LG, Hansen S, Hjort L, Madsen CM, Kampmann FB, Thuesen ACB, Granstrømi C, Strøm M, Maslova E, **Frikke-Schmidt R**, Damm P, Chavarro JE, Hu FB, Olsen SF, Vaag A. Increased adiposity and associated dysmetabolic traits including earlier onset of puberty in adolescent offspring of women with gestational diabetes mellitus. *Diabetes Care* 2017;40:1746-1755.
- 107) Madsen CM, Varbo A, Tybjærg-Hansen A, **Frikke-Schmidt R**, Nordestgaard BG. U-shaped relationship of high-density lipoprotein and risk of infectious disease: two prospective population-based cohort studies. *Eur Heart J* 2018;39:1181-1190.
- 108) Turcot V, Lu Y, Highland HM et al. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure underpinning obesity. *Nat Genet*;2018;50:26-41.
- 109) Kjeldsen EW, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. ABCA7 and risk of dementia and vascular disease in the Danish population. *Ann Clin Trans Neurol*;2017;5:41-51.
- 110) Mathiesen IH, Pressler T, Otorai P, Katzenstein TL, **Frikke-Schmidt R**, Hitz MF. Osteoporosis and associated factors among adults with cystic fibrosis. *Int J Endocrinol* 2018;48:3974.
- 111) Qayyum F, Lauridsen BK, Stender S, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Genetic variants in CYP7A1 and risk of myocardial infarction and symptomatic gallstone disease. *Eur Heart J* 2018;39:2106-2116.
- 112) Nordestgaard LT, Tybjærg-Hansen A, Rasmussen KL, Nordestgaard BG, **Frikke-Schmidt R**. Genetic variation in clusterin and risk of dementia and ischemic vascular disease in the general population – cohort studies and meta-analyses of 362,338 individuals. *BMC Medicine* 2018;16:39.
- 113) Oldoni F, van Capelleveen JC, Danila N, van de Sluis B, Wolters JC, Heeren J, Sinke RJ, Hui D, Dallinga-Thie GM, **Frikke-Schmidt R**, Hovingh GK, Tybjærg-Hansen A, Kuivenhoven JA. Naturally occurring mutations in human LRP1 affect HDL metabolism through ABCA1 and SR-B1. *Arterioscler Thromb Vasc Biol* 2018;38:1440-1453.
- 114) Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. Absolute 10 year risk of dementia by age, gender, and APOE genotype for targeted prevention – 104,537 individuals from the general population. *CMAJ* 2018;190:E1033-E1041.
- 115) Frydland M, Møller JE, Wiberg S, Lindholm MG, Hansen R, Henriques JPS, Møller-Helgestad OK, Bang LE, Goetze JP, **Frikke-Schmidt R**, Udesen NLJ, Thomsen JH, Ouweneel D, Obling L, Ravn HB, Holmvang L, Jensen LO, Kjaergaard J, Hassager C. Serum lactate is a prognostic factor in patients admitted with suspected ST-elevation myocardial infarction. *Shock* 2019; 51:321-327.
- 116) Rasmussen KL, Nordestgaard BG, Danesh J, **Frikke-Schmidt R**, Nielsen SF. Complement C3 and risk of dementia: a mendelian randomization study of 120,000 individuals. *Alzheimers Dement* 2018;14:1589-1601.
- 117) Sillesen AS et al. Copenhagen Baby Heart Study: a population study of newborns with prenatal inclusion. *Eur J Epidemiol* 2019;34:79-90.

- 118) Juul Rasmussen I, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. Blood-brain barrier transcytosis genes and risk of dementia – a study of 75,474 individuals. *Eur J Epidemiol* 2019;34:579-590.
- 119) Emerging Risk Factor Collaboration. Comparing cardiovascular risk factors for venous and arterial thrombosis: individual-participant data meta-analysis of 1.1 million participants in 76 prospective cohorts. *JAMA Cardiol* 2019;4:163-173.
- 120) Jensen CS, Simonsen AH, Siersma V, Beyer N, Frederiksen KS, Gottrup H, Hoffman K, Høgh P, **Frikke-Schmidt R**, Sobol NA, Waldemar G, Wermuth L, Hasselbalch SG. Patients with Alzheimer’s disease who carry the APOE ε4 allele benefit more from physical exercise. *Alzheimers Dement (N Y)* 2019;5:99-106.
- 121) Klein A, Wiberg S, Hassager C, Winther-Jensen M, **Frikke-Schmidt R**, Bang LE, Lindholm MG, Holmvang L, Moeller-Helgestad O, Ravn HB, Jensen LO, Moeller JE, Frydland M. Admission leukocyte count is associated with late cardiogenic shock development and all-cause 30-day mortality in patients with ST-elevation myocardial infarction. *Schock* 2019 May 1 [Epub ahead of print].

### Letters/commentaries

- 122) In reply to Batalla A, Reguero JR, Hevia S, Cubero GI, Cortina A. Mild hypercholesterolemia and premature heart disease. Nordestgaard B, **Frikke-Schmidt R**, Tybjærg-Hansen A. *J Am Coll Cardiol* 2001;37:331-332.
- 123) In reply to Brunham LR, Kastelein JJP. ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease. Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. *JAMA* 2008;300:1997-1998.
- 124) Varbo A, Benn M, Tybjærg-Hansen A, Jørgensen AB, **Frikke-Schmidt R**, Nordestgaard BG. Response: Lipoprotein subclass profiling reveals pleiotropy in the genetic variants of lipid risk factors for coronary heart disease: A note on mendelian randomization studies. *J Am Coll Cardiol* 2013;62:1908-1909.
- 125) Christoffersen M, **Frikke-Schmidt R**, Schnohr P, Jensen GB, Nordestgaard BG, Tybjærg-Hansen A. Response to letter regarding article, “visible age-related signs and risk of ischemic heart disease in the general population: a prospective cohort study”. *Circulation* 2014;130:e338.doi
- 126) **Frikke-Schmidt R**. Commentary on “Temporal trend in dementia incidence since 2002 and projections for prevalence in England and Wales to 2040: modelling study. *BMJ* 2017;358:j2856”. *Dan Med Bull* 2017.
- 127) **Frikke-Schmidt R**. Commentary on “Does cognitive training prevent cognitive decline? *Ann Intern Med* 2018;168:63-68”. *Dan Med Bull* 2018.
- 128) **Frikke-Schmidt R**. Commentary on “Contribution of alcohol use disorder to the burden of dementia in France 2008-13: a nationwide retrospective cohort study. *Lancet Public Health* 2018;3:e124-32”. *Dan Med Bull* 2018.

### Reviews in Danish

- 129) Rasmussen KL, **Frikke-Schmidt R**. Plasmaniveau af apolipoprotein E og prædiktion af demens. *Klinisk Biokemi i Norden* 2015;27:20-25.

### Patents

- 130) Soluble CD163 and prediction of disease. “Methods of Prognosis”. Application No./patent No. 10776928.3 – 2404 PCT/DK2010050260.

### Resubmitted or submitted papers

- 131) Rasmussen KL, Tybjærg-Hansen A, Nordestgaard BG, **Frikke-Schmidt R**. Plasma levels of apolipoprotein E, APOE genotype, all-cause and cause-specific mortality in 105,949 individuals from the general population. *Resubmitted to Eur Heart J*.



- 132) Rimbart A, Dalila N, Wolters JC, Huijkman N, Smit M, Kloosterhuis N, Riemsma M, van der Veen Y Singla A, van Dijk F, Nordestgaard BG, **Frikke-Schmidt R**, Burstein E, Tybjærg-Hansen A, van de Sluis B, Kuivenhoven JA. A common variant in CCDC93 decreases LDL-C and protects against myocardial infarction by regulating endosomal trafficking of LDL-receptor. *Resubmitted to Eur Heart J*.
- 133) Madrid A, Rasmussen KL, Rode L, Nordestgaard BG, **Frikke-Schmidt R**, Bojesen SE. Observational and genetic studies of short telomere length and Alzheimer disease. *To be resubmitted to Eur J Epidemiol*.
- 134) Frydland M, Møller JE, Lindholm MG, Hansen R, Wiberg S, Møller-Helgestad OK, Thomsen JH, Gøtze JP, Engstrøm T, **Frikke-Schmidt R**, Ravn BH, Holmvang L, Jensen LO, Kjærgaard J, Hassager C. Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction. *Submitted to BMJ Heart*.
- 135) Lee C. et al. Nordestgaard LT and **Frikke-Schmidt R**. Association of anthropometry and weight change with risk of dementia and its major subtypes: a meta-analysis consisting of 2.8 million adults with 57,294 cases of dementia. *Resubmitted to BMJ*.
- 136) Shelly C, Grandjean P, Ouhote Y, Plomgaard P, **Frikke-Schmidt R**, Nielsen F, Zmirou-Navier D, Weihe P, Valvi D. Early life exposures to perfluoroalkyl substances in relation to adipokine hormone levels at birth and over the childhood period. *Resubmitted to JCEM*.
- 137) Ottesen NM, Meluken I, **Frikke-Schmidt R**, Plomgaard P, Scheike T, Fernandes BS, Dodd S, Berk M, Enghausen H, Kessing LV, Miskowiak K, Vinberg M. Are remitted affective disorders and high familial risk of affective disorders associated with metabolic syndrome and peripheral markers of inflammation and oxidative stress? – a monozygotic twin study. *Resubmitted to Psychological Medicine*.
- 138) Benn M, Tybjærg-Hansen A, Nordestgaard B, **Frikke-Schmidt R**. Glucose and risk of Alzheimer's disease, vascular dementia and unspecified dementia: Mendelian randomization studies in 125,875 individuals. *Submitted to Int J Epidemiol*.
- 139) Greve A, Christoffersen M, **Frikke-Schmidt R**, Nordestgaard BG, Tybjærg-Hansen A. Low plasma transthyretin and risk of heart failure in the general population. *Submitted to JACC*.
- 140) Thomassen JQ, Tolstrup JS, Benn M, **Frikke-Schmidt R**. Type 2 diabetes and risk of dementia: observational and Mendelian randomization studies in <1 million individuals. *Submitted to Eur J Epidemiol*.
- 141) Ottesen NH, Meluken I, **Frikke-Schmidt R**, Plomgaard P, Scheike T, Kessing LV, Miskowiak K, Vinberg M. S100B and brain derived neurotrophic factor in monozygotic twins with, at risk of and without affective disorders. *Submitted to Journal of Affective Disorders*.

### Manuscripts in preparation

- 142) Juul Rasmussen I, Rasmussen KL, Nordestgaard BG, Tybjærg-Hansen A, **Frikke-Schmidt R**. Ten year absolute risk charts for dementia – a tool for stratified clinical trials and targeted prevention. In preparation.
- 143) Hegazy SH, Nordestgaard BG, Tybjærg-Hansen, **Frikke-Schmidt R**. High-sensitivity C-Reactive Protein and risk of dementia in the general population. In preparation.
- 144) Kjeldsen EW, Thomassen JQ, Nordestgaard BG, Tybjærg-Hansen A, **Frikke-Schmidt R**. Very high plasma HDL cholesterol and risk of dementia in the general population: A prospective cohort study. In preparation.
- 145) Dalila N, **Frikke-Schmidt R**, Odorni F, Kuivenhoven JA, Nordestgaard BG, Tybjærg-Hansen A. Genetic variation in GPR146 and risk of ischemic heart disease – a study of 108,166 individuals from the general population. In preparation.
- 146) Nordestgaard LT, Lauridsen BK, Christoffersen M, Afzal S, Nordestgaard BG, **Frikke-Schmidt R**, Tybjærg-Hansen A. Genetic variation in the CETP gene and risk of ischemic heart disease, cardiovascular mortality, age-related macular degeneration and dementia. In preparation.

## Publications – Ruth Frikke-Schmidt

---

- 147) Rasmussen KL, Tybjærg-Hansen, Nordestgaard BG, **Frikke-Schmidt R**. Contribution of rare genetic variation in *APOE* to risk of dementia in the general population – a cohort study of 105,000 individuals. In preparation.
- 148) Juul Rasmussen I, Rasmussen KL, Nordestgaard BG, Tybjærg-Hansen A, **Frikke-Schmidt R**. Is smoking causally related to dementia? – a mendelian randomization study in 110,000 individuals from the general population. In preparation.
- 149) Lee C, Nissen Bonde A, Thomassen JQ, **Frikke-Schmidt R**, Torp-Pedersen C, Gislason G. Disease progression, HbA1c and choice of antidiabetic treatment – a nationwide study of biochemistry and registry data. In preparation.
- 150) Russo F, Banasik K, **Frikke-Schmidt R**, Brunak S. Exploring the direct and inverse comorbidities in dementia and related diseases. In preparation.